Skip to main content
SpringerLink
Log in

MicroRNAs in Therapy and Toxicity

  • Protocol
  • First Online:
Epigenetics and Gene Expression in Cancer, Inflammatory and Immune Diseases

Part of the book series: Methods in Pharmacology and Toxicology ((MIPT))

Abstract

Identification of clinically important microRNAs (miRNAs) has developed over the last few years, and has become increasingly important in testing the role of miRNAs in healthy and diseased tissue states. Here we discuss the protocols of use in the laboratory for testing such roles of miRNAs in drug therapy and toxicity. Moreover, we describe the protocols necessary in a step-by-step practical guide to identify miRNA species, as well as the in vitro use of miRNA-modulating agents, to test the role of miRNAs in clinically important samples.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9:775–789

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Miska EA, Alvarez-Saavedra E, Abbott AL, Lau NC, Hellman AB, McGonagle SM, Bartel DP, Ambros VR, Horvitz HR (2007) Most Caenorhabditis elegans microRNAs are individually not essential for development or viability. PLoS Genet 3, e215

    Article  PubMed  PubMed Central  Google Scholar 

  3. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ (2003) Dicer is essential for mouse development. Nat Genet 35:215–217

    Article  CAS  PubMed  Google Scholar 

  4. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C, Gay R, Buckley CD, Tak PP, Gay S, Kyburz D (2011) Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 63:373–381

    Article  PubMed  PubMed Central  Google Scholar 

  5. Filkova M, Aradi B, Senolt L, Ospelt C, Vettori S, Mann H, Filer A, Raza K, Buckley CD, Snow M, Vencovsky J, Pavelka K, Michel BA, Gay RE, Gay S, Jungel A (2014) Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann Rheum Dis 73:1898–1904

    Article  CAS  PubMed  Google Scholar 

  6. Wang WX, Huang Q, Hu Y, Stromberg AJ, Nelson PT (2011) Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 121:193–205

    Article  PubMed  Google Scholar 

  7. Yang G, Song Y, Zhou X, Deng Y, Liu T, Weng G, Yu D, Pan S (2015) MicroRNA-29c targets beta-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo. Mol Med Rep 12:3081–3088

    CAS  PubMed  Google Scholar 

  8. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E (2011) MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20:3067–3078

    Article  CAS  PubMed  Google Scholar 

  9. de Mena L, Coto E, Cardo LF, Diaz M, Blazquez M, Ribacoba R, Salvador C, Pastor P, Samaranch L, Moris G, Menendez M, Corao AI, Alvarez V (2010) Analysis of the micro-RNA-133 and PITX3 genes in Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 153b:234–1239

    Google Scholar 

  10. Dohner K, Dohner H (2008) Molecular characterization of acute myeloid leukemia. Haematol-Hematol J 93:976–982

    Article  Google Scholar 

  11. Mi SL, Lu J, Sun M, Li ZJ, Zhang H, Neilly MB, Wang Y, Qian ZJ, Jin J, Zhang YM, Bohlander SK, Le Beau MM, Larson RA, Golub TR, Rowley JD, Chen JJ (2007) MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 104:19971–19976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM (2008) MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183–3189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu SJ, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD (2010) Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 28:5257–5264

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Shah NM, Rushworth SA, Murray MY, Bowles KM, MacEwan DJ (2013) Understanding the role of NRF2-regulated miRNAs in human malignancies. Oncotarget 4:1130–1142

    Article  PubMed  PubMed Central  Google Scholar 

  15. Elton TS, Selemon H, Elton SM, Parinandi NL (2013) Regulation of the MIR155 host gene in physiological and pathological processes. Gene 532:1–12

    Article  CAS  PubMed  Google Scholar 

  16. O’Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205:585–594

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG (2003) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 101:2074

    Article  CAS  PubMed  Google Scholar 

  18. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S (2012) MiR-125 in normal and malignant hematopoiesis. Leukemia 26:2011–2018

    Article  CAS  PubMed  Google Scholar 

  19. Bousquet M, Quelen C, Rosati R, Mansat-De Mas R, La Starza R, Bastard C, Lippert E, Talmant P, Lafage-Pochitaloff M, Leroux D, Gervais C, Viguie F, Lai JL, Terre C, Beverlo B, Sambani C, Hagemeijer A, Marynen P, Delsol G, Dastugue N, Mecucci C, Brousset P (2008) Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med 205:2499–2506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bousquet M, Harris M, Zhou BY, Fleming MD, Lodish H (2010) MicroRNA Mir-125b causes leukemia. Blood 116:1299

    Article  Google Scholar 

  21. Rushworth SA, Zaitseva L, Murray MY, Shah NM, Bowles KM, MacEwan DJ (2012) The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappa B and underlies its chemo-resistance. Blood 120:5188–5198

    Article  CAS  PubMed  Google Scholar 

  22. Shah NM, Zaitseva L, Bowles KM, MacEwan DJ, Rushworth SA (2015) NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. Cell Death Differ 22:654–664

    Article  CAS  PubMed  Google Scholar 

  23. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485

    Article  CAS  PubMed  Google Scholar 

  24. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451–455

    Article  PubMed  Google Scholar 

  25. Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ, Fattinger K (2005) Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 61:135–143

    Article  PubMed  Google Scholar 

  26. Vuppalanchi R, Liangpunsakul S, Chalasani N (2007) Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 102:558–562, quiz 693

    Article  PubMed  Google Scholar 

  27. Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini M (2012) Current challenges and controversies in drug-induced liver injury. Drug Saf 35:1099–1117

    Article  CAS  PubMed  Google Scholar 

  28. Moggs J, Moulin P, Pognan F, Brees D, Leonard M, Busch S, Cordier A, Heard DJ, Kammuller M, Merz M, Bouchard P, Chibout SD (2012) Investigative safety science as a competitive advantage for pharma. Expert Opin Drug Metab Toxicol 8:1071–1082

    Article  CAS  PubMed  Google Scholar 

  29. Antoine DJ, Mercer AE, Williams DP, Park BK (2009) Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica 39:565–577

    Article  CAS  PubMed  Google Scholar 

  30. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67

    Article  CAS  PubMed  Google Scholar 

  31. Biomarkers Definitions Working G (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95

    Article  Google Scholar 

  32. Ratner M (2005) FDA pharmacogenomics guidance sends clear message to industry. Nat Rev Drug Discov 4:359

    Article  CAS  PubMed  Google Scholar 

  33. Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Padro T, Planatscher H, Rossi A, Schneiderhan-Marra N, Schuppe-Koistinen I, Thomann P, Vidal JM, Molac B (2011) A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today 16:600–608

    Article  PubMed  Google Scholar 

  34. Watkins PB (2011) Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 89:788–790

    Article  CAS  PubMed  Google Scholar 

  35. Zen K, Zhang CY (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32:326–348

    Article  PubMed  Google Scholar 

  36. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106:4402–4407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S (2010) Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56:1830–1838

    Article  CAS  PubMed  Google Scholar 

  38. Harrill AH, Roach J, Fier I, Eaddy JS, Kurtz CL, Antoine DJ, Spencer DM, Kishimoto TK, Pisetsky DS, Park BK, Watkins PB (2012) The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 92:214–220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Antoine DJ, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, Park BK (2013) Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 58:777–787

    Google Scholar 

  40. Dear JW, Antoine DJ, Starkey-Lewis P, Goldring CE, Park BK (2013) Letter to the editor: early detection of paracetamol toxicity using circulating liver microRNA and markers of cell necrosis. Br J Clin Pharmacol. doi: 10.1111/bcp.12214

  41. Thulin P, Nordahl G, Gry M, Yimer G, Aklillu E, Makonnen E, Aderaye G, Lindquist L, Mattsson CM, Ekblom B, Antoine DJ, Park BK, Linder S, Harrill AH, Watkins PB, Glinghammar B, Schuppe-Koistinen I (2014) Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 34:367–378

    Google Scholar 

  42. Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54:1767–1776

    Article  CAS  PubMed  Google Scholar 

  43. Holman NS, Mosedale M, Wolf KK, LeCluyse EL, Watkins PB (2016) Subtoxic alterations in hepatocyte-derived exosomes: an early step in drug-induced liver injury? Toxicol Sci 151:365–375

    Article  CAS  PubMed  Google Scholar 

  44. Yang D, Yuan Q, Balakrishnan A, Bantel H, Klusmann JH, Manns MP, Ott M, Cantz T, Sharma AD (2016) MicroRNA-125b-5p mimic inhibits acute liver failure. Nat Commun 7:11916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Vliegenthart AD, Starkey Lewis P, Tucker CS, Del Pozo J, Rider S, Antoine DJ, Dubost V, Westphal M, Moulin P, Bailey MA, Moggs JG, Goldring CE, Park BK, Dear JW (2014) Retro-orbital blood acquisition facilitates circulating microRNA measurement in zebrafish with paracetamol hepatotoxicity. Zebrafish 11:219–226

    Google Scholar 

  46. Sharkey JW, Antoine DJ, Park BK (2012) Validation of the isolation and quantification of kidney enriched miRNAs for use as biomarkers. Biomarkers 17:231–239

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Ashton Street, Liverpool, L69 3GE, UK

    David J. MacEwan, Niraj M. Shah & Daniel J. Antoine

Authors
  1. David J. MacEwan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niraj M. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel J. Antoine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. MacEwan .

Editor information

Editors and Affiliations

  1. Department of Nutrition Science, Purdue University, West Lafayette, Indiana, USA

    Barbara Stefanska

  2. Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine University of Liverpool, Liverpool, United Kingdom

    David J. MacEwan

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

MacEwan, D.J., Shah, N.M., Antoine, D.J. (2017). MicroRNAs in Therapy and Toxicity. In: Stefanska, B., MacEwan, D. (eds) Epigenetics and Gene Expression in Cancer, Inflammatory and Immune Diseases. Methods in Pharmacology and Toxicology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6743-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6743-8_10

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6741-4

  • Online ISBN: 978-1-4939-6743-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation